Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alector
Biotech
AbbVie dumps Alector's Alzheimer's immunotherapy after phase 1
AbbVie has severed its ties to the potential Alzheimer’s disease immunotherapy—and the asset has vanished from Alector’s pipeline.
Nick Paul Taylor
Jul 8, 2022 6:04am
With GSK, Alector to capitalize on big moment in Alzheimer's
Jan 27, 2022 9:35am
COVID-19 vaccine mandates a mixed bag in biotech
Aug 11, 2021 8:10am
Alector bolsters 'immuno-neurology' approach with early data
Jul 30, 2021 10:15am
GSK, under pressure to perform, pens $2.2B deal with Alector
Jul 2, 2021 7:30am
Beyond COVID-19, where will biopharma focus in 2021?
Jan 22, 2021 11:00am
